112 related articles for article (PubMed ID: 3166483)
21. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
Kuzuya K; Nozaki M; Chihara T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
[TBL] [Abstract][Full Text] [Related]
23. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
24. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
25. CA125 antigen levels in obstetric and gynecologic patients.
Niloff JM; Knapp RC; Schaetzl E; Reynolds C; Bast RC
Obstet Gynecol; 1984 Nov; 64(5):703-7. PubMed ID: 6208522
[TBL] [Abstract][Full Text] [Related]
26. [Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels].
Iwanari O; Miyako J; Date Y; Moriyama M; Yoshino N; Kijima S; Nakayama S; Ryuhkoh K; Moriyama M; Hata T
Nihon Gan Chiryo Gakkai Shi; 1989 Jun; 24(6):1256-60. PubMed ID: 2571650
[TBL] [Abstract][Full Text] [Related]
27. Circulating mucins as tumor markers in ovarian cancer (review).
Devine PL; McGuckin MA; Ward BG
Anticancer Res; 1992; 12(3):709-17. PubMed ID: 1622128
[TBL] [Abstract][Full Text] [Related]
28. [Clinical usefulness of serum sialyl Le(x)-i measurement in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):15-9. PubMed ID: 2564410
[TBL] [Abstract][Full Text] [Related]
29. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
[TBL] [Abstract][Full Text] [Related]
30. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
[TBL] [Abstract][Full Text] [Related]
31. [Serum sialyl Tn antigen as a prognostic marker in patients with epithelial ovarian cancer].
Kobayashi H; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):14-20. PubMed ID: 1541859
[TBL] [Abstract][Full Text] [Related]
32. [Tumor markers in gynecologic diseases].
Geyer H; Kleine W
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
[TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors].
Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
Rinsho Byori; 1985 Feb; 33(2):173-7. PubMed ID: 3858562
[No Abstract] [Full Text] [Related]
34. Roles of CA125 in patients with ovarian cancer--usefulness in periodical monitoring.
Kawai M; Inagaki S; Yamashita H; Imaizumi H; Kakihara M; Arii Y
Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1059-67. PubMed ID: 3166484
[No Abstract] [Full Text] [Related]
35. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
37. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Karino K; Endoh J; Kitao M
Gynecol Obstet Invest; 1990; 29(3):214-8. PubMed ID: 1972688
[TBL] [Abstract][Full Text] [Related]
38. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
39. [Serum sialyl-Tn antigen in colorectal cancer and its relationship to prognosis].
Yamaguchi A; Tukioka Y; Fushida S; Kurosaka Y; Kanno M; Yonemura Y; Miwa K; Miyazaki I
Gan To Kagaku Ryoho; 1992 Mar; 19(3):349-53. PubMed ID: 1543361
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
Yakushiji M; Nishimura H
Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
